<DOC>
	<DOCNO>NCT02387762</DOCNO>
	<brief_summary>This study evaluate safety , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) efficacy ACP-196 subject Rheumatoid Arthritis background Methotrexate .</brief_summary>
	<brief_title>ACP-196 Versus Placebo Subjects With Rheumatoid Arthritis Background Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Main Diagnosis RA accord 2010 ACR/EULAR Classification Criteria . Must stable MTX dose ( 7.5 25 mg/week ) Subjects must able read understand consent form , complete studyrelated procedure , communicate study staff . Are willing able adhere study visit schedule , understand comply protocol requirement . Main Prior malignancy , except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer subject disease free â‰¥ 5 year . A lifethreatening illness , medical condition organ system dysfunction , investigator 's opinion , could compromise subject 's safety , interfere absorption metabolism ACP196 , put study outcome undue risk . Subjects take investigational drug within previous 30 day randomization . Use synthetic diseasemodifying antirheumatic drug ( DMARDS ) limit leflunomide , azathioprine , cyclosporine , penicillamine gold salt within 8 week randomization . Use etanercept , anakinra , tofacitinib within 4 week randomization . Use abatacept , humira , infliximab , tocilizumab within 8 week randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Acalabrutinib</keyword>
</DOC>